Si-Bone Inc (SIBN)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $1.06B
Last updated: Nov 17, 2026 at 11:05 AM ET
Si-Bone Inc (SIBN) Earnings: Report Dates and Results
In the quarter ended Sep 30, 2026, Si-Bone reported EPS of -$0.08, above the -$0.13 estimate. It beat the EPS estimate in each of the last 17 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
SIBN's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.
SIBN Earnings Call
The latest SIBN earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 33 quarters below that had an estimate, SIBN beat 21, missed 11 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $55.70M, up 14.5% from $48.66M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.08 | -$0.13 | -$0.17 - -$0.08 | +38.46% | Beat | N/A | 8 | N/A | Nov 2, 2026 | $55.70M |
| Jun 30, 2026 | -$0.09 | -$0.15 | -$0.17 - -$0.12 | +40.00% | Beat | N/A | 8 | 2 up, 1 down | Aug 3, 2026 | $56.01M |
| Mar 31, 2026 | -$0.10 | -$0.19 | -$0.24 - -$0.16 | +47.37% | Beat | N/A | 7 | 1 up, 5 down | May 11, 2026 | $52.59M |
| Dec 31, 2025 | -$0.04 | -$0.13 | -$0.14 - -$0.11 | +69.23% | Beat | N/A | 9 | 0 up, 2 down | Feb 23, 2026 | $56.35M |
| Sep 30, 2025 | -$0.11 | -$0.16 | -$0.20 - -$0.14 | +31.25% | Beat | N/A | 8 | 4 up, 0 down | Nov 10, 2025 | $48.66M |
| Jun 30, 2025 | -$0.14 | -$0.18 | -$0.23 - -$0.15 | +22.22% | Beat | N/A | 8 | 6 up, 1 down | Aug 4, 2025 | $48.63M |
| Mar 31, 2025 | -$0.15 | -$0.22 | -$0.27 - -$0.18 | +31.82% | Beat | N/A | 8 | 2 up, 3 down | May 5, 2025 | $47.29M |
| Dec 31, 2024 | -$0.11 | -$0.13 | -$0.18 - -$0.01 | +18.09% | Beat | N/A | 7 | 0 up, 1 down | Feb 24, 2025 | $49.00M |
| Sep 30, 2024 | -$0.16 | -$0.24 | -$0.29 - -$0.20 | +33.33% | Beat | N/A | 9 | 0 up, 0 down | Nov 12, 2024 | $40.34M |
| Jun 30, 2024 | -$0.22 | -$0.28 | -$0.30 - -$0.24 | +21.43% | Beat | N/A | 9 | 0 up, 0 down | Aug 5, 2024 | $39.97M |
| Mar 31, 2024 | -$0.27 | -$0.31 | -$0.37 - -$0.26 | +12.90% | Beat | N/A | 9 | 0 up, 0 down | May 6, 2024 | $37.87M |
| Dec 31, 2023 | -$0.27 | -$0.28 | -$0.31 - -$0.23 | +3.57% | Beat | N/A | 8 | 0 up, 0 down | Feb 26, 2024 | $38.86M |
| Sep 30, 2023 | -$0.25 | -$0.34 | -$0.40 - -$0.29 | +26.47% | Beat | N/A | 8 | 0 up, 0 down | Nov 6, 2023 | $34.01M |
| Jun 30, 2023 | -$0.30 | -$0.40 | -$0.48 - -$0.30 | +25.00% | Beat | N/A | 8 | 1 up, 0 down | Aug 7, 2023 | $33.30M |
| Mar 31, 2023 | -$0.32 | -$0.42 | -$0.45 - -$0.36 | +23.81% | Beat | N/A | 7 | 0 up, 0 down | May 1, 2023 | $32.71M |
| Dec 31, 2022 | -$0.32 | -$0.40 | -$0.46 - -$0.32 | +20.00% | Beat | N/A | 8 | 1 up, 0 down | Feb 27, 2023 | $31.95M |
| Sep 30, 2022 | -$0.41 | -$0.47 | -$0.53 - -$0.44 | +12.77% | Beat | N/A | 8 | 0 up, 0 down | Nov 7, 2022 | $26.43M |
| Jun 30, 2022 | -$0.54 | -$0.49 | N/A | -10.20% | Miss | N/A | N/A | 0 up, 1 down | Aug 8, 2022 | $25.59M |
| Mar 31, 2022 | -$0.52 | -$0.43 | -$0.52 - -$0.36 | -20.93% | Miss | N/A | 7 | 0 up, 0 down | May 9, 2022 | $22.44M |
| Dec 31, 2021 | -$0.43 | -$0.39 | -$0.47 - -$0.33 | -10.26% | Miss | N/A | 7 | N/A | Feb 28, 2022 | $25.23M |
| Sep 30, 2021 | -$0.48 | -$0.41 | -$0.46 - -$0.35 | -17.07% | Miss | N/A | 7 | 0 up, 0 down | Nov 8, 2021 | $22.29M |
| Jun 30, 2021 | -$0.42 | -$0.39 | -$0.44 - -$0.34 | -7.69% | Miss | N/A | 8 | N/A | Aug 2, 2021 | $22.19M |
| Mar 31, 2021 | -$0.37 | -$0.39 | -$0.44 - -$0.34 | +5.13% | Beat | N/A | 7 | N/A | May 3, 2021 | $20.44M |
| Dec 31, 2020 | -$0.28 | -$0.30 | -$0.34 - -$0.26 | +6.67% | Beat | N/A | 7 | N/A | Mar 8, 2021 | $22.14M |
| Sep 30, 2020 | -$0.33 | -$0.42 | -$0.42 - -$0.35 | +21.43% | Beat | N/A | 7 | N/A | Nov 2, 2020 | $20.37M |
| Jun 30, 2020 | -$0.44 | -$0.63 | -$0.71 - -$0.60 | +30.16% | Beat | N/A | 7 | N/A | Aug 3, 2020 | $14.05M |
| Mar 31, 2020 | -$0.47 | -$0.38 | -$0.41 - -$0.35 | -23.68% | Miss | N/A | 6 | N/A | May 4, 2020 | $16.82M |
| Dec 31, 2019 | -$0.36 | -$0.35 | -$0.40 - -$0.26 | -2.86% | Miss | N/A | 7 | N/A | Mar 9, 2020 | $19.81M |
| Sep 30, 2019 | -$0.46 | -$0.37 | -$0.39 - -$0.36 | -24.32% | Miss | N/A | 4 | N/A | Nov 11, 2019 | $16.18M |
| Jun 30, 2019 | -$0.35 | -$0.35 | -$0.42 - -$0.25 | 0.00% | In line | N/A | 4 | N/A | Aug 6, 2019 | $16.32M |
| Mar 31, 2019 | -$0.38 | -$0.25 | -$0.27 - -$0.24 | -52.00% | Miss | N/A | 4 | N/A | May 8, 2019 | $14.99M |
| Dec 31, 2018 | -$0.22 | -$0.21 | -$0.22 - -$0.20 | -4.76% | Miss | N/A | 4 | N/A | Mar 7, 2019 | $15.62M |
| Sep 30, 2018 | -$0.30 | -$0.28 | N/A | -7.14% | Miss | N/A | N/A | N/A | Oct 18, 2018 | $13.38M |
| Jun 30, 2018 | -$0.19 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 29, 2018 | $13.66M |
| Mar 31, 2017 | -$0.30 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jun 29, 2017 | $11.43M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$0.44, after -$0.76 the year before. It was -$1.01 for the year ended Dec 31, 2018, the oldest of the 8 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$0.44 | N/A |
| Dec 31, 2024 | -$0.76 | N/A |
| Dec 31, 2023 | -$1.14 | N/A |
| Dec 31, 2022 | -$1.79 | N/A |
| Dec 31, 2021 | -$1.70 | N/A |
| Dec 31, 2020 | -$1.52 | N/A |
| Dec 31, 2019 | -$1.55 | N/A |
| Dec 31, 2018 | -$1.01 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 8,900 words across 13 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 8,861 | 13 | |
| 2026Q2 | Jun 30, 2026 | 5,816 | 11 | |
| 2026Q1 | Mar 31, 2026 | 6,351 | 12 | |
| 2025Q4 | Dec 31, 2025 | 6,105 | 10 | |
| 2025Q3 | Sep 30, 2025 | 8,612 | 12 | |
| 2025Q2 | Jun 30, 2025 | 7,519 | 11 | |
| 2025Q1 | Mar 31, 2025 | 8,396 | 10 | |
| 2024Q4 | Dec 31, 2024 | 7,390 | 11 |
2026Q3 Earnings Call
Opening remarks
Saqib Iqbal Vice President, FP&A and Investor Relations Earlier today, SI-BONE released financial results for the quarter ended September 30, 2026. A copy of the press release is available on the company's website. Before we begin, I'd like to remind you that management's remarks today may include forward-looking statements within the meaning of federal securities laws, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties, including those set forth in our SEC filings, such as our most recent Form 10-K and Form 10-Q, and actual results may differ materially from any forward-looking statements that we make today. Accordingly, you should not place undue reliance on these statements. These forward-looking statements speak only as of the date that they are made, and we do not assume any obligation to update any forward-looking statements, except as required by law. During the call, management may also discuss certain non-GAAP measures, including adjusted EBITDA and free cash flow. Unless otherwise noted, any reference to profitability is in terms of positive adjusted EBITDA. For a reconciliation of these non-GAAP measures to GAAP accounting, please see the company's full earnings release issued earlier today. Unless otherwise noted, all results are compared to the comparable period in the prior year. With that, I'll turn the call over to Laura.
Laura Francis CEO Thanks, Saqib. Good afternoon, and thank you for joining us. We delivered a solid third quarter with accelerating procedure demand, broader physician adoption and improving financial performance. These results reflect disciplined execution of our multiyear strategy to expand our differentiated platform into new clinical applications. By focusing on anatomy-specific solutions that enable durable fixation and fusion in patients with compromised bone, we're reaching more patients and expanding our growth opportunity. Worldwide revenue grew approximately 15% to $55.7 million. U.S. revenue increased approximately 14% to $52.8 million. U.S. procedure volume increased approximately 20%, supported by 16% growth in active physicians. The strong double-digit volume growth across all procedure types demonstrates that our targeted platform expansion and call point diversification strategies are delivering. In addition to the strong surgeon demand in the third quarter, demand accelerated for our expanded INTRA platform from interventional spine physicians in the office space and ASC sites of care. Our decision to build differentiated solutions with applications across all sites of care has made INTRA the preferred platform for this call point. International revenue grew 27% to $2.9 million, supported by continued adoption of technologies launched in the last 12 months. We converted the revenue growth into stronger financial performance. Adjusted EBITDA increased 32%, more than twice the pace of revenue growth, while working capital discipline contributed to stronger operating cash flow.
Frequently Asked Questions About SIBN
Did SIBN beat earnings estimates last quarter?
Yes. Si-Bone reported EPS of -$0.08 for the quarter ended Sep 30, 2026, above the -$0.13 estimate, a 38.46% surprise.
What EPS do analysts expect from SIBN next quarter?
The consensus EPS estimate for Si-Bone for the quarter ending Dec 31, 2026 is -$0.07 from 11 analysts, with estimates from -$0.09 to -$0.05.
How often does SIBN beat earnings estimates?
Si-Bone beat the EPS estimate in each of the last 17 quarters, with an average surprise of +28.10%.
SIBN pages: Overview, Earnings, Forecast, Financials, Competitors